Dako to Develop Companion Dx for Merck Cancer Drug | GenomeWeb

NEW YORK (GenomeWeb) – Agilent Technologies' Dako business said today that it will develop a companion diagnostic test for a cancer drug being developed by Merck.

The test will be for the analysis of the potential tumor biomarker PD-L1 as an aid in treating cancer patients with Merck's investigational anti-PD-1 antibody. Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.